Who we are
ZBRA Pharma is a boutique commercialization partner for rare disease and specialty care in Korea and Asia-Pacific. We bridge global biotech innovation with the Korean market, helping companies bring innovative therapies to the patients who need them, from regulatory approval and reimbursement to sustained commercial success.
Founded by a senior leader with more than 20 years of rare disease commercialization at Sanofi Genzyme, Shire, and Takeda, ZBRA combines a deep understanding of Korea's healthcare ecosystem with a track record of successful market launches. Drawing on hands-on experience with MFDS, HIRA, and NHIS, we help clients secure timely approval and sustainable reimbursement through smart pricing strategies such as RSA and indication-based pricing.
We also bring the ZBRA Expert Network (ZEN), a curated network of leading KOLs, former industry executives, and market access specialists built on long-standing, trusted relationships. ZEN gives clients direct access to the clinical and commercial insights that shape successful launches.
Beyond market entry, we help companies revitalize existing businesses, build specialized teams, and strengthen their strategic and marketing capabilities, so that local teams have the skills to drive success long after launch. For emerging biotechs, our lean entry model offers a path into Korea without the cost and risk of building a full local subsidiary.
ZBRA Pharma is your trusted partner to launch, grow, and thrive in Korea's rare disease and specialty care market.
Expertise
1. Market entry & expansion
Feasibility, pricing & reimbursement strategy, and the right local partners before you commit capital.
2. End-to-end commercialization
As MA holder, we own regulatory approval, distribution, and sales execution across the Korean system.
3. Strategy & capability building
We refine commercial strategy and build the specialized rare-disease teams that sustain it.
4. Commercial operations & partnerships
Co-promotion, CSO deployment, and key-account management measured against real performance.
Our Solution
Across the full commercialization journey
Enter and win in Korea — without building a subsidiary.
We take rare disease and specialty care therapies from market assessment to full commercial operations — as your advisor, or as your MA holder on the ground.
1. Assess
Market Entry & Feasibility
Should you enter Korea — and how?
We assess the opportunity, the pricing & reimbursement pathway, and the right partners, so you commit with evidence, not assumptions.
↳ RSA · IBP · ODD access strategy
2. Enter
Virtual Subsidiary
Launch without a Korean entity. As your MA holder, we own regulatory approval, distribution, and sales execution — your full Korea operation, without the fixed overhead.
↳ MA holdership · end-to-end commercialization
3. Build
Strategy & Capability Building
Build the team that sustains the launch. We refine commercial strategy and stand up specialized rare-disease teams — on demand, through our expert network, instead of full-time hires.
↳ ZEN — ZBRA Expert Network
4. Grow
Commercial Operations & Partnerships
Grow through the right channels. Co-promotion, CSO deployment, and key-account management across hospitals and KOLs — measured against real performance.
↳ co-promotion · CSO · KAM
TRACK RECORD
Two Decades in Rare Disease
Case 1
Achondroplasia
(Skeletal / Growth)
<18 mo fastest-ever P&R · 80%+ patient uptake in 3 months
Stood up a new organization and launched a first-in-class therapy through a Lean Entry model — backed by sharp P&R negotiation to secure access at speed.
Case 2
HAE & CMV
(Immunology / Virology)
HAE — Sequential launch of on-demand and prophylaxis therapies, reshaping the market by expanding diagnosis. 6% → 40% HAE diagnosis rate lifted
CMV — Second-line therapy launch enabled through Early Access (EAP) and Patient Support (PSP) programs.
Case 3
LSDs — Fabry · Gaucher · MPS
(Metabolic)
2 organizations, 4 brands launched
Built two commercial organizations and launched four brands, with AI-based diagnostic infrastructure driving a paradigm shift toward sustainable growth.
Business turnaround — Led 3× business take-backs and commercial restructuring to relaunch and revitalize the franchise.
Selected Engagements
"Where Strategy Meets Execution"
Strategy, commercialization, and policy work across rare disease and specialty care
1. Pharma Strategy & Commercialization
• Due diligence and market-entry assessment for neurodegenerative and specialty care therapies in Korea
• Pricing & reimbursement strategy — RSA, expenditure cap, and outcome-based assessment
• Salesforce KPI benchmarking & optimization to lift commercial performance
• Advised on Early Access (EAP) and Named Patient Programs (NPP) for earlier therapy access
• Designed and executed GTM and commercialization plans leading to successful launches
2. Market Entry & Business Establishment
• Market insights across rare and specialty care in Korea & Taiwan
• Supported multinationals in establishing local entities and operating models
• Developed patient support programs improving access and adherence
• Guided diagnostic and biomarker applications for precision medicine
• Competitive landscape analyses for strategic positioning in Korea
3. Focused Therapy-Area Market Insight
• Lysosomal Storage Disorder (LSD) management strategies
• Fabry disease market research across Asia
• hATTR-CM and cardiovascular specialty care evaluations
• Hemophilia drug launch strategy in Korea
• HAE commercialization and market access in Asia
4. Strategic Policy & Thought Leadership
• Authored an Asia Alzheimer's Disease (AD) white paper shaping regional policy dialogue on diagnosis and access
• Developed an operational proposal for Indication-Based Pricing (IBP) in Korea's reimbursement system
• Engaged payers and industry task forces on rare disease market-access policy